Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Santen, Arctic Vision to Launch ARVN001 in China
Clearside Biomedical has announced that Arctic Vision, its Asia-Pacific partner, has signed a commercial collaboration agreement with Santen Pharmaceutical Co. for ARVN001 (known in the United States as XIPERE) to treat uveitic macular edema (UME) and additional ophthalmic indications in…
FDA Approves LumiThera’s Valeda for Dry AMD Treatment
The U.S. FDA has granted LumiThera authorization to market its Valeda Light Delivery System, the first FDA-authorized device designed to treat vision loss in patients with dry age-related macular degeneration (AMD). This significant approval, obtained through the De Novo authorization…
FDA Clears HG202 CRISPR Therapy for Wet AMD Trials
The U.S. FDA has granted investigational drug clearance for HG202, a pioneering CRISPR/Cas13Y RNA-editing therapy developed by HuidaGene to treat neovascular (wet) age-related macular degeneration (AMD). This milestone makes HG202 the first CRISPR/Cas13Y RNA-targeting therapy in clinical development and the…
BlueRock Therapeutics’ OpCT-001 Receives FDA Clearance
BlueRock Therapeutics, a subsidiary of Bayer, announced that the FDA has cleared its investigational new drug (IND) application for OpCT-001, a stem cell therapy designed to treat primary photoreceptor diseases. The clearance allows BlueRock to initiate a phase 1/2a clinical…
$6.4M Grant for New Dry AMD & Stargardt Treatments
Dr. Christopher Cioffi, the Thomas and Constance D’Ambra Professor in Organic Chemistry at Rensselaer Polytechnic Institute, is collaborating with Dr. Konstantin Petrukhin, Professor of Ophthalmic Science at Columbia University, to develop promising compounds aimed at treating dry age-related macular degeneration…
Promising Drug for Preventing Diabetic Eye and Kidney Disease
New research led by the University of Bristol has identified a promising type of inhibitor drug that could potentially prevent microvascular diabetic complications, including diabetic eye and kidney disease. The study, published in Cardiovascular Diabetology, focuses on protecting the glycocalyx,…
Aviceda’ Kicks off Phase II/III SIGLEC Trial for AMD
Aviceda Therapeutics has initiated the second part of its Phase II/III SIGLEC trial for AVD-104, an ophthalmic candidate aimed at treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The company has dosed the first subject in this phase,…
CDC Investigates Multistate Outbreak Related to Artificial Tears
A recent investigation led by the Centers for Disease Control and Prevention (CDC) has shed light on a multistate outbreak of carbapenemase-producing, carbapenem-resistant Pseudomonas aeruginosa, linked to the use of artificial tears. The details of the investigation were published in…
Foundation Fighting Blindness Launches Gyrate Atrophy Study
The Foundation Fighting Blindness has launched a natural history study targeting gyrate atrophy, a rare and sight-threatening inherited retinal disease. Spearheading this initiative are esteemed researchers Dr. Mandeep S. Singh, MD, PhD, and Dr. David Valle, MD, from the Wilmer…
FDA Clears Eyenuk’s Additional Camera for DR Detection
Eyenuk has received FDA clearance to utilize the Topcon NW400 retinal camera with its EyeArt AI system for automated detection of diabetic retinopathy (DR). This clearance complements the system’s existing clearance for usage with Canon CR-2 AF and Canon CR-2…